Core Insights - Lulu's Fashion Lounge Holdings, Inc. reported a net revenue of $81.5 million for Q2 2025, an 11% decrease year-over-year, attributed to a 16% decline in total orders placed, partially offset by a 1% increase in average order value [8][11] - The company achieved positive Adjusted EBITDA of $0.5 million, compared to a loss of $0.2 million in the same period last year, indicating improved operational efficiency [8][30] - Lulu's continues to focus on strategic initiatives to enhance cost efficiency and expand its customer base, particularly in the occasion dress segment, while repositioning its casual wear and footwear offerings [2][3] Financial Performance - Net loss for Q2 2025 was $3.0 million, a significant improvement from a net loss of $10.8 million in Q2 2024 [8][11] - Gross profit decreased by 12% to $36.9 million, with a gross margin of 45.3%, down 20 basis points from the previous year [8][30] - Active customers decreased by 8% to 2.5 million compared to 2.7 million in the same period last year [8][30] Debt and Liquidity - Total debt decreased by $4.3 million to $5.8 million, while net debt increased by $2.7 million to $4.2 million during the quarter [8][30] - The company is negotiating a new asset-based revolving credit facility to strengthen its liquidity position [3][6] Future Outlook - Lulu's expects to achieve positive Adjusted EBITDA in Q3 2025 and projects full-year capital expenditures to be approximately $2.5 million [9][10] - The company remains optimistic about its strategic initiatives and the potential for improved financial performance in the upcoming quarters [3][9]

Core Insights - Aterian, Inc. reported financial results for Q2 2025, highlighting challenges due to tariff volatility and a strategic focus on cost optimization and new product launches [1][2]. Financial Performance - Net revenue for Q2 2025 was $19.5 million, down from $28.0 million in Q2 2024, primarily due to macroeconomic conditions and lower unit volumes from price increases related to tariffs [6]. - Gross margin decreased to 54.3% from 60.4%, attributed to changes in product mix and tariff impacts on pricing and cost of goods sold [6]. - Adjusted EBITDA loss for Q2 2025 was $(2.2) million compared to an Adjusted EBITDA of $0.2 million in Q2 2024 [6][33]. Cost Management and Strategic Initiatives - The company expects annual pre-tax savings of approximately $5.5 million from workforce reductions and vendor savings initiatives, with initial benefits anticipated in the second half of 2025 [2]. - Aterian is diversifying its manufacturing footprint, reducing reliance on high-tariff regions, and has sourced approximately 65% of its dehumidifiers from China in 2025, down from 100% in 2024 [11] [2]. Future Guidance - Aterian anticipates net revenue for the six months ending December 31, 2025, to be between $36 million and $38 million, with Adjusted EBITDA expected to range from a loss of $(1.0) million to break-even [3]. - The company aims to launch new products, including the Squatty Potty flushable wipes, in September 2025, marking its entry into the consumables market [2]. Operational Highlights - Total operating expenses decreased to $15.1 million in Q2 2025 from $20.1 million in Q2 2024, with restructuring costs of $1.8 million included in the Q2 2025 expenses [6]. - The total cash balance at June 30, 2025, was $10.5 million, down from $18.0 million at December 31, 2024 [6].

Core Insights - Fossil Group, Inc. reported a second quarter 2025 net sales of $220 million, a decrease of 15.2% compared to the same period in 2024, primarily due to category softness and a decline in smartwatch sales [5][11] - The company achieved a gross margin of 57.5%, an increase of 490 basis points year-over-year, attributed to improved product margins and reduced freight costs [5][11] - Operating income for the second quarter was $8 million, with an operating margin of 3.9%, marking a significant improvement from a loss of $34 million in the prior year [11][12] - Fossil Group announced a comprehensive refinancing plan aimed at strengthening its balance sheet and increasing liquidity [3][4] Financial Performance - Net sales for the second quarter totaled $220.4 million, down from $260 million in Q2 2024, with declines across all major regions: 19% in the Americas, 14% in Europe, and 12% in Asia [5][11] - Gross profit was $126.7 million, a decline of 7.4% from $136.9 million in the previous year, but gross margin improved to 57.5% from 52.6% [5][11] - Operating expenses decreased by 30.8% to $118.2 million, representing 53.7% of net sales compared to 65.7% in the prior year [5][6] Outlook and Guidance - The company raised its full-year 2025 financial guidance, reflecting strong year-to-date results and ongoing progress in its turnaround strategy [8][12] - Worldwide net sales are expected to decline in the mid-teens, an improvement from previous guidance of a decline in the mid to high teens [12] - Adjusted operating margin is anticipated to be break-even to slightly positive, compared to prior guidance of negative low single digits [12] Balance Sheet and Liquidity - As of July 5, 2025, Fossil Group had total liquidity of $110.6 million, including $109.9 million in cash and cash equivalents [7] - Total debt stood at $179 million, with inventories decreasing by 11.9% to $178.1 million compared to the previous year [7][11]

Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop work order; Follow-up for all participants dosed, including 400-person sentinel cohort continues Cash, cash equivalents and investments of $26.3 million as of June 30, 2025; Current runway into 2026 Conference call today at 4:30 p.m ...

MONTEVIDEO, Uruguay, Aug. 13, 2025 (GLOBE NEWSWIRE) -- DLocal Limited (“dLocal”, “we”, “us”, and “our”) (NASDAQ:DLO), a technology - first payments platform, today announced the appointment of Guillermo López Pérez as Chief Financial Officer, who will join us in the next few months. Guillermo will report to dLocal’s CEO, Pedro Arnt. This appointment further strengthens dLocal’s outstanding leadership team. “We are very excited to welcome Guillermo as our new CFO," said Pedro Arnt, CEO of dLocal. "He brings ...

RONAN, Mont., Aug. 13, 2025 (GLOBE NEWSWIRE) -- AirJoule Technologies Corporation (NASDAQ: AIRJ) (“AirJoule Technologies” or the “Company”), a leading technology platform that unleashes the power of water from air, today announced its second quarter 2025 results. Second Quarter 2025 & Recent Highlights Key Milestones A250™ Product Expands AirJoule® Technology Platform: The A250™ system will be commercialized for the industrial dehumidification market, which is largely serviced by inefficient legacy technolo ...

Q2 2025 Sales Growth of 134% to $3.0 Million Fueled by Strong Demand for New Products and Technologies Records Two of the Most Successful Months of Sales in Company History in Q2 2025 Sixth Consecutive Quarter of Sales Growth REDMOND, Ore., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Expion360 Inc. (Nasdaq: XPON) (“Expion360” or the “Company”), an industry leader in lithium iron phosphate battery power storage, today reported its financial and operational results for the first quarter ended June 30, 2025. Second Qua ...

Core Insights - Allogene Therapeutics is advancing its clinical programs, particularly the ALPHA3 trial for cema-cel and the ALLO-329 trial for autoimmune diseases, indicating a focused strategy for value creation in cell therapies [2][3][4] Program Updates - The ALPHA3 trial has been amended to a randomized study comparing cema-cel after standard fludarabine and cyclophosphamide (FC) lymphodepletion to observation, with over 50 clinical sites activated across the U.S. and Canada [3][5][7] - Early data from the ALPHA3 trial shows promising minimal residual disease (MRD) conversion rates and a favorable safety profile for cema-cel following standard FC lymphodepletion [4][5] - The ALLO-329 trial, targeting autoimmune diseases, has launched a Phase 1 RESOLUTION basket trial, with the first clinical update expected in the first half of 2026 [6][8] Financial Results - As of June 30, 2025, the company reported a net loss of $50.9 million, or $0.23 per share, with total operating expenses of $56.8 million [15][21] - The company ended the second quarter with $302.6 million in cash, cash equivalents, and investments, projecting a cash runway into the second half of 2027 [11][15][23]

Wa'el Hashad Wa'el Hashad, CEO, Longeveron Full enrollment achieved for pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric disease and orphan-designated indicationELPIS II top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in late 2026, if ELPIS II results are p ...

Results surpassed expectations across key metrics including biomass production, revenue, gross profit, and Adjusted EBITDAWholesale biomass production was 230,748 pounds, up 54% year-over-yearCost of production was $91 per pound, a substantial improvement compared to $148 per pound in Q2 2024Second quarter 2025 revenue was $59.9 million, exceeding guidance and up 11% year-over-yearGross margin was 53%, compared to 45% in Q1 2025 and 53% in Q2 2024Adjusted EBITDA of $18.1 million, considerably higher than gu ...